Barcelona clinic liver cancer(BCLC)intermediate stage hepatocellular carcinoma is a heterogenous disease.Transarterial chemoembolization is offered as the first line therapy in this disease stage.Recent advances in sy...Barcelona clinic liver cancer(BCLC)intermediate stage hepatocellular carcinoma is a heterogenous disease.Transarterial chemoembolization is offered as the first line therapy in this disease stage.Recent advances in systemic therapy have markedly improved outcomes even in advanced stage disease.The use of systemic therapy in BCLC intermediate stage disease may now be of therapeutic benefit in selected patients.We will focus on“the up to seven”criteria and its utility in selecting systemic therapy.展开更多
Liver cancer accounts for 4.7%of all newly diagnosed cancers and 8.2%of cancer deaths annu-ally.Hepatocellular carcinoma(HCC)accounts for the majority of primary liver cancers.There are 2 curative strategies in HCC:re...Liver cancer accounts for 4.7%of all newly diagnosed cancers and 8.2%of cancer deaths annu-ally.Hepatocellular carcinoma(HCC)accounts for the majority of primary liver cancers.There are 2 curative strategies in HCC:resection and transplant.Unfortunately,50%of patients who undergo resection will relapse in 2 years and many patients on transplant lists become ineligible for transplant due to disease progression.The majority of patients still require systemic therapies.Tyrosine kinase inhibitors have successfully extended the overall survival in patients with hepa-tocellular carcinoma.However,these treatments have been noted to cause severe side effects in-cluding liver toxicity,hypertension,gastrointestinal toxicity and cutaneous adverse effects.This article will focus on the adverse skin reactions seen during the treatment of hepatocellular carci-noma by various tyrosine kinase inhibitors.The focus will be symptomatology,management,and whether the development of cutaneous toxicities can be prognostic.展开更多
文摘Barcelona clinic liver cancer(BCLC)intermediate stage hepatocellular carcinoma is a heterogenous disease.Transarterial chemoembolization is offered as the first line therapy in this disease stage.Recent advances in systemic therapy have markedly improved outcomes even in advanced stage disease.The use of systemic therapy in BCLC intermediate stage disease may now be of therapeutic benefit in selected patients.We will focus on“the up to seven”criteria and its utility in selecting systemic therapy.
文摘Liver cancer accounts for 4.7%of all newly diagnosed cancers and 8.2%of cancer deaths annu-ally.Hepatocellular carcinoma(HCC)accounts for the majority of primary liver cancers.There are 2 curative strategies in HCC:resection and transplant.Unfortunately,50%of patients who undergo resection will relapse in 2 years and many patients on transplant lists become ineligible for transplant due to disease progression.The majority of patients still require systemic therapies.Tyrosine kinase inhibitors have successfully extended the overall survival in patients with hepa-tocellular carcinoma.However,these treatments have been noted to cause severe side effects in-cluding liver toxicity,hypertension,gastrointestinal toxicity and cutaneous adverse effects.This article will focus on the adverse skin reactions seen during the treatment of hepatocellular carci-noma by various tyrosine kinase inhibitors.The focus will be symptomatology,management,and whether the development of cutaneous toxicities can be prognostic.
